Washington, October 17: The US National Institutes of Health (NIH) has started a Phase III clinical trial to evaluate the safety and effectiveness of 3 immunity modulator drugs in hospitalized Kovid-19 adult patients. Indeed, the immune response was experienced in Kovid-19 patients, whose immune system released a lot of protein and promoted inflammation. The purpose of this clinical trial is to determine whether the immune response can reduce the need for ventilators and reduce patients’ hospital stay.
According to the report of the news agency Xinhua, a trial named Active-1 Immune Modulator will determine whether the therapy can balance the highly active immune system. The trial is expected to be conducted on approximately 2,100 patients admitted to Kovid hospitals in the United States and Latin America.
Also read: Coronavirus Cases Update: 198 new cases of corona virus infection registered in Arunachal, two security personnel included, total number of infected reached 10 thousand
Those involved in the trial were given a placebo or immune modulator. According to NIH, will study various types of combinations in relation to severity of illness, speed of recovery, mortality and resource utilization of hospitals.